

Biosimilar Monoclonal Antibodies Market Size, Trends, Analysis, and Outlook By Product (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab, Others), By Application (Oncology, Chronic & Autoimmune Diseases, Others), by Region, Country, Segment, and Companies, 2024-2030

<https://marketpublishers.com/r/B036A773A413EN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: B036A773A413EN

Abstracts

The global Biosimilar Monoclonal Antibodies market size is poised to register 20.64% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Biosimilar Monoclonal Antibodies market across By Product (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab, Others), By Application (Oncology, Chronic & Autoimmune Diseases, Others).

The Biosimilar Monoclonal Antibodies Market is witnessing significant growth and market expansion driven by the increasing demand for cost-effective biologic therapies, the expiration of patent protection for blockbuster biologic drugs, and the development of biosimilar monoclonal antibody products targeting oncology, autoimmune diseases, and chronic inflammatory conditions. Biosimilar monoclonal antibodies are highly similar versions of approved originator monoclonal antibody drugs, offering comparable efficacy, safety, and immunogenicity profiles at reduced costs, thereby increasing patient access to life-saving biologic treatments and driving market competition. Key trends include the development of biosimilar manufacturing platforms, analytical characterization methods, and clinical trial designs to demonstrate biosimilarity, equivalence, and extrapolation of clinical data for biosimilar monoclonal antibody products across diverse therapeutic indications and patient populations. Additionally, there is a growing emphasis on regulatory pathways, interchangeability designation,

and pharmacovigilance requirements to ensure the quality, safety, and effectiveness of biosimilar monoclonal antibody products throughout their lifecycle, from manufacturing and regulatory approval to post-market surveillance and market access. Moreover, collaborative partnerships between biosimilar developers, contract manufacturing organizations (CMOs), and healthcare payers are essential for advancing biosimilar development programs, establishing market acceptance, and promoting widespread adoption of biosimilar monoclonal antibody therapies, fostering innovation and affordability in biologic drug markets worldwide.

Biosimilar Monoclonal Antibodies Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Biosimilar Monoclonal Antibodies market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Biosimilar Monoclonal Antibodies survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Biosimilar Monoclonal Antibodies industry.

Key market trends defining the global Biosimilar Monoclonal Antibodies demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Biosimilar Monoclonal Antibodies Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Biosimilar Monoclonal Antibodies industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Biosimilar Monoclonal Antibodies companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Biosimilar Monoclonal Antibodies industry

Leading Biosimilar Monoclonal Antibodies companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Biosimilar Monoclonal Antibodies companies.

Biosimilar Monoclonal Antibodies Market Study- Strategic Analysis Review

The Biosimilar Monoclonal Antibodies market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Biosimilar Monoclonal Antibodies Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Biosimilar Monoclonal Antibodies industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Biosimilar Monoclonal Antibodies Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Biosimilar Monoclonal Antibodies Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Biosimilar Monoclonal Antibodies market segments. Similarly, Strong end-user demand is encouraging Canadian Biosimilar Monoclonal Antibodies companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Biosimilar Monoclonal Antibodies market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Biosimilar Monoclonal Antibodies Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Biosimilar Monoclonal Antibodies industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Biosimilar Monoclonal Antibodies market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Biosimilar Monoclonal Antibodies Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing

investments in healthcare infrastructure drive the demand for Biosimilar Monoclonal Antibodies in Asia Pacific. In particular, China, India, and South East Asian Biosimilar Monoclonal Antibodies markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Biosimilar Monoclonal Antibodies Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Biosimilar Monoclonal Antibodies Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Biosimilar Monoclonal Antibodies market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Biosimilar Monoclonal Antibodies.

Biosimilar Monoclonal Antibodies Market Company Profiles

The global Biosimilar Monoclonal Antibodies market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AbbVie Inc, Biocon, Coherus BioSciences, Novartis AG, Pfizer

Recent Biosimilar Monoclonal Antibodies Market Developments

The global Biosimilar Monoclonal Antibodies market study presents recent market news

and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Biosimilar Monoclonal Antibodies Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Product

Infliximab

Rituximab

Abciximab

Biosimilar Monoclonal Antibodies Market Size, Trends, Analysis, and Outlook By Product (Infliximab, Rituximab,...

Trastuzumab

Adalimumab

Bevacizumab

Others

By Application

Oncology

Chronic & Autoimmune Diseases

Others

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

AbbVie Inc

Biocon

Coherus BioSciences

Novartis AG

Pfizer

Formats Available: Excel, PDF, and PPT

Contents

1. EXECUTIVE SUMMARY

- 1.1 Biosimilar Monoclonal Antibodies Market Overview and Key Findings, 2024
- 1.2 Biosimilar Monoclonal Antibodies Market Size and Growth Outlook, 2021- 2030
- 1.3 Biosimilar Monoclonal Antibodies Market Growth Opportunities to 2030
- 1.4 Key Biosimilar Monoclonal Antibodies Market Trends and Challenges
 - 1.4.1 Biosimilar Monoclonal Antibodies Market Drivers and Trends
 - 1.4.2 Biosimilar Monoclonal Antibodies Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Biosimilar Monoclonal Antibodies Companies

2. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE OUTLOOK TO 2030

- 2.1 Biosimilar Monoclonal Antibodies Market Size Outlook, USD Million, 2021- 2030
- 2.2 Biosimilar Monoclonal Antibodies Incremental Market Growth Outlook, %, 2021-2030
- 2.3 Segment Snapshot, 2024

3. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
 - * Threat of New Entrants
 - * Threat of Substitutes
 - * Intensity of Competitive Rivalry
 - * Bargaining Power of Buyers
 - * Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

4. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SEGMENTATION ANALYSIS AND OUTLOOK

- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Product

Infliximab

Rituximab

Abciximab

Trastuzumab

Adalimumab

Bevacizumab

Others

By Application

Oncology

Chronic & Autoimmune Diseases

Others

4.3 Growth Prospects and Niche Opportunities, 2023- 2030

4.4 Regional comparison of Market Growth, CAGR, 2023-2030

5. REGION-WISE MARKET OUTLOOK TO 2030

5.1 Key Findings for Asia Pacific Biosimilar Monoclonal Antibodies Market, 2025

5.2 Asia Pacific Biosimilar Monoclonal Antibodies Market Size Outlook by Type, 2021-2030

5.3 Asia Pacific Biosimilar Monoclonal Antibodies Market Size Outlook by Application, 2021- 2030

5.4 Key Findings for Europe Biosimilar Monoclonal Antibodies Market, 2025

5.5 Europe Biosimilar Monoclonal Antibodies Market Size Outlook by Type, 2021- 2030

5.6 Europe Biosimilar Monoclonal Antibodies Market Size Outlook by Application, 2021-2030

5.7 Key Findings for North America Biosimilar Monoclonal Antibodies Market, 2025

5.8 North America Biosimilar Monoclonal Antibodies Market Size Outlook by Type, 2021- 2030

5.9 North America Biosimilar Monoclonal Antibodies Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Biosimilar Monoclonal Antibodies Market, 2025

5.11 South America Pacific Biosimilar Monoclonal Antibodies Market Size Outlook by Type, 2021- 2030

5.12 South America Biosimilar Monoclonal Antibodies Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Biosimilar Monoclonal Antibodies Market, 2025

5.14 Middle East Africa Biosimilar Monoclonal Antibodies Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Biosimilar Monoclonal Antibodies Market Size Outlook by Application, 2021- 2030

6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030

6.1 US Biosimilar Monoclonal Antibodies Market Size Outlook and Revenue Growth Forecasts

6.2 US Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.3 Canada Market Size Outlook and Revenue Growth Forecasts

6.4 Canada Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.6 Mexico Market Size Outlook and Revenue Growth Forecasts

6.6 Mexico Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.7 Germany Market Size Outlook and Revenue Growth Forecasts

6.8 Germany Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.9 France Market Size Outlook and Revenue Growth Forecasts

6.10 France Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.11 UK Market Size Outlook and Revenue Growth Forecasts

6.12 UK Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.13 Spain Market Size Outlook and Revenue Growth Forecasts

6.14 Spain Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.16 Italy Market Size Outlook and Revenue Growth Forecasts

6.16 Italy Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts

6.18 Rest of Europe Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.19 China Market Size Outlook and Revenue Growth Forecasts

6.20 China Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.21 India Market Size Outlook and Revenue Growth Forecasts

6.22 India Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.23 Japan Market Size Outlook and Revenue Growth Forecasts

6.24 Japan Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.26 South Korea Market Size Outlook and Revenue Growth Forecasts

6.26 South Korea Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.27 Australia Market Size Outlook and Revenue Growth Forecasts

6.28 Australia Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts

6.30 South East Asia Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts

- 6.32 Rest of Asia Pacific Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Biosimilar Monoclonal Antibodies Industry Drivers and Opportunities

7. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET OUTLOOK ACROSS SCENARIOS

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

8. BIOSIMILAR MONOCLONAL ANTIBODIES COMPANY PROFILES

- 8.1 Profiles of Leading Biosimilar Monoclonal Antibodies Companies in the Market
 - 8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
 - 8.3 Financial Performance and Key Metrics
- AbbVie Inc
Biocon
Coherus BioSciences
Novartis AG
Pfizer

9. APPENDIX

- 9.1 Scope of the Report
- 9.2 Research Methodology and Data Sources
- 9.3 Glossary of Terms
- 9.4 Market Definitions
- 9.5 Contact Information

I would like to order

Product name: Biosimilar Monoclonal Antibodies Market Size, Trends, Analysis, and Outlook By Product (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab, Others), By Application (Oncology, Chronic & Autoimmune Diseases, Others), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/B036A773A413EN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B036A773A413EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970